Trials / Unknown
UnknownNCT02968394
Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions
Influence of Omalizumab Co-treatment on Honey-bee Venom Immunotherapy Failure Due to Systemic Reactions
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 11 (estimated)
- Sponsor
- The University Clinic of Pulmonary and Allergic Diseases Golnik · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate if omalizumab co-treatment may allow reintroduction of honey bee venom immunotherapy in patients with immunotherapy treatment failure due to systemic reactions.
Detailed description
Some honey bee venom allergic patients cannot be treated with venom immunotherapy due to systemic reactions during immunotherapy - immunotherapy failure due to systemic reactions. High basophil allergen sensitivity is a risk factor for venom immunotherapy failure due to systemic reactions. Omalizumab decreases basophil sensitivity. Venom immunotherapy failure patients will be co-treated with omalizumab during another attempt of immunotherapy introduction. Patients will be clinically and immunologically followed up after the introduction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | omalizumab |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2017-03-01
- First posted
- 2016-11-18
- Last updated
- 2016-11-21
Locations
1 site across 1 country: Slovenia
Source: ClinicalTrials.gov record NCT02968394. Inclusion in this directory is not an endorsement.